Evidence map›Paper›PMID 40948663›Full record

Trial reportBlood neoplasia2025

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis.

Aaron S Rosenberg, Emanual Maverakis, Caitlin Costello, Elizabeth A Brem, Matthew Joseph Wieduwilt, Guillaume Luxardi, Paul Kaesberg, Keon Abedi, Samantha Herbert, Joseph Tuscano

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aaron S RosenbergDivision of Malignant Hematology/Cellular Therapy and Transplantation, University of California Davis School of Medicine, Sacramento, CA.
Emanual MaverakisDepartment of Dermatology, University of California Davis School of Medicine, Sacramento, CA.
Caitlin CostelloDepartment of Medicine, Division of Bone Marrow Transplant, University of California San Diego Moores Cancer Center, La Jolla, CA.
Elizabeth A BremDivision of Hematology & Oncology, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA.
Matthew Joseph WieduwiltDivision of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC.
Guillaume LuxardiDepartment of Ophthalmology & Visual Sciences, University of California Davis, Sacramento, CA.
Paul KaesbergDivision of Malignant Hematology/Cellular Therapy and Transplantation, University of California Davis School of Medicine, Sacramento, CA.
Keon AbediUniversity of California Berkeley, Berkeley, CA.
Samantha HerbertDepartment of Dermatology, University of California Davis School of Medicine, Sacramento, CA.
Joseph TuscanoDivision of Malignant Hematology/Cellular Therapy and Transplantation, University of California Davis School of Medicine, Sacramento, CA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clarithromycin is a macrolide antibiotic with anti-multiple myeloma (MM) activity when combined with dexamethasone and immunomodulatory agents. This phase 1/2 study of clarithromycin, ixazomib, pomalidomide, and dexamethasone (ClIPd) assessed tolerability and efficacy in relapsed/refractory MM. The primary end points were the maximal tolerated and recommended phase 2 dose. Key secondary end points were the overall response rate (ORR) (≥partial response), disease control rate (DCR) (≥stable disease), progression-free survival (PFS), and overall survival (OS). All 4 medications were given at full dose for 6 cycles. Pomalidomide, ixazomib, and dexamethasone were given at reduced doses with full-dose clarithromycin in subsequent maintenance cycles until unacceptable toxicity or progression. Clarithromycin was withheld during weeks 1 to 2 of cycle 1 to facilitate correlative studies. A total of 28 patients were evaluable for response/survival. The ORR was 75%; DCR was 100%; 56% achieved ≥very good partial response (VGPR), whereas 14% achieved complete response (CR)/stringent CR. High-risk cytogenetics were not associated with ORR (Fisher exact test,

Identifiers

PMID40948663
PMCPMC12432457

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.